These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 26655953)

  • 1. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
    Gai Z; Gui T; Hiller C; Kullak-Ublick GA
    J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
    Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
    J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
    Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
    Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome Activation.
    Xu Y; Yang C; Zhang S; Li J; Xiao Q; Huang W
    Biol Pharm Bull; 2018 Nov; 41(11):1638-1644. PubMed ID: 30135326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.
    Zhu JB; Xu S; Li J; Song J; Luo B; Song YP; Zhang ZH; Chen YH; Xie DD; Yu DX; Xu DX
    Eur J Pharmacol; 2018 Nov; 838():60-68. PubMed ID: 30196109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage.
    Gai Z; Chu L; Xu Z; Song X; Sun D; Kullak-Ublick GA
    Sci Rep; 2017 Aug; 7(1):9815. PubMed ID: 28852062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
    J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
    Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
    Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
    [No Abstract]   [Full Text] [Related]  

  • 12. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice.
    Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C
    Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
    Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
    Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uninephrectomy augments the effects of high fat diet induced obesity on gene expression in mouse kidney.
    Gai Z; Hiller C; Chin SH; Hofstetter L; Stieger B; Konrad D; Kullak-Ublick GA
    Biochim Biophys Acta; 2014 Sep; 1842(9):1870-8. PubMed ID: 25016146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
    PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.
    Wang XX; Jiang T; Shen Y; Caldas Y; Miyazaki-Anzai S; Santamaria H; Urbanek C; Solis N; Scherzer P; Lewis L; Gonzalez FJ; Adorini L; Pruzanski M; Kopp JB; Verlander JW; Levi M
    Diabetes; 2010 Nov; 59(11):2916-27. PubMed ID: 20699418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
    Wu H; Liu G; He Y; Da J; Xie B
    Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.